Sign in

CELZ on Nasdaq

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

In its 2026 annual report the company says: “We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our subsidiary, Creative Medical Technologies, Inc., was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction, which it acquired in February 2016.”3 It is headquartered in Phoenix, Arizona.1 Its shares trade on Nasdaq under the symbol CELZ.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Allogene Therapeutics, Inc., Senti Biosciences Holdings, Inc. or OPTHEA LIMITED, or pick any stock.

  • TickerCELZ on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersPhoenix, Arizona1
  • Incorporated inNV2
  • Business address211 E. Osborn Rd., Phoenix, Az 850122
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

63.4%Gross margin4
-102380.2%Operating margin4
-99916.8%Net margin4
-45.5%Revenue growth, 20254
-79.8%Return on equity4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue0¢$2.2K
  • Research and development38¢$2.3M
  • Selling, general and admin62¢$3.8M

Out of $6.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$6.0K in 2025−96% since 2019
0$50.0K$100.0K$150.0K$200.0K2019: $165.5K$165.5K20192020: $164.5K$164.5K2020−1%2021: $87.8K$87.8K2021−47%2022: $88.6K$88.6K2022+1%2023: $9.0K$9.0K2023−90%2024: $11.0K$11.0K2024+22%2025: $6.0K$6.0K2025−45%
Gross profit567894$3.8K in 2025−97% since 2019
0$50.0K$100.0K$150.0K2019: $120.0K$120.0K20192020: $113.9K$113.9K2020−5%2021: $39.8K$39.8K2021−65%2022: $60.1K$60.1K2022+51%2023: $5.4K$5.4K2023−91%2024: $6.6K$6.6K2024+22%2025: $3.8K$3.8K2025−42%
Operating income567894-$6.1M in 2025+444% since 2019
-$15.0M-$10.0M-$5.0M02019: -$1.1M-$1.1M20192020: -$1.1M-$1.1M2020−1%2021: -$3.1M-$3.1M2021+180%2022: -$10.2M-$10.2M2022+228%2023: -$5.6M-$5.6M2023−45%2024: -$5.7M-$5.7M2024+2%2025: -$6.1M-$6.1M2025+7%
Net income567894-$6.0M in 2025−29% since 2019
-$40.0M-$20.0M0$20.0M2019: -$8.5M-$8.5M20192020: -$36.3M-$36.3M2020+328%2021: $19.2M$19.2M20212022: -$10.1M-$10.1M20222023: -$5.3M-$5.3M2023−48%2024: -$5.5M-$5.5M2024+4%2025: -$6.0M-$6.0M2025+9%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues$6.0K$11.0K
Cost of revenues$2.2K$4.4K
Gross profit$3.8K$6.6K
Research and development$2.3M$2.4M
Selling, general and administrative$3.8M$3.2M
Amortization of patent costs$123.3K$110.5K
TOTAL EXPENSES$6.1M$5.8M
Operating loss-$6.1M-$5.7M
Interest income$147.8K$250.4K
Total other income (expense)$147.8K$250.4K
LOSS BEFORE PROVISION FOR INCOME TAXES-$6.0M-$5.5M
Provision for income taxes$0$0
NET LOSS-$6.0M-$5.5M
Net income attributable to non-controlling interest$0$0
NET LOSS ATTRIBUTABLE TO CMTH-$6.0M-$5.5M
NET LOSS PER SHARE - BASIC AND DILUTED-$2.52-$3.71
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED2.4M shares1.5M shares

Compare CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. with another company

Corporate structure

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

  • Timothy Warbington Filed SCHEDULE 13D on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., latest Oct 1, 2026
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., latest Aug 14, 2025 (2 filings since May 15, 2025)
  • John Markey Filed SC 13G/A on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., latest May 26, 2023 (2 filings since May 2, 2023)
  • Altium Capital Management LLC Filed SC 13G/A on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., latest Feb 14, 2022 (2 filings since Dec 20, 2021)
  • CVI Investments, Inc. Filed SC 13G/A on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., latest Feb 14, 2022 (2 filings since Dec 10, 2021)
  • L1 Capital Global Opportunities Master Fund, Ltd. Filed SC 13G/A on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., latest Feb 14, 2022 (2 filings since Dec 8, 2021)
  • CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Phoenix, Arizona

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, net$407.2K4 Dec 31, 2025$530.6K4 Dec 31, 2024−23.2%
Patents, net$300.0K4 Dec 31, 2025

Inventory

ItemLatestA year beforeChange
Inventory, total$04 Dec 31, 2025$2.2K4 Dec 31, 2024−100.0%

Properties, in its own words

We do not currently own any real property. Our corporate office is located at 211 East Osborn Road, Phoenix, Arizona, which we lease on a month-to-month basis. Management believes that this space is adequate to meet our current and foreseeable needs.

Item 2 of the 10-K filed Mar 20, 2026.3

Leadership

Who has led CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Timothy Warbington2016–now

President

  1. Steven L. White2009–2016
  2. Timothy Warbington2016–now
2010201520202025
Board members and other officers (5)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorDonald Dickerson named May 5, 202217
  • DirectorMichael H. Finger named May 5, 202217

Former names

  • JOLLEY MARKETING INCSep 13, 2002 to May 13, 20162

Timeline

  1. Sep 25, 20268-K Entered a material agreement; Unregistered sale of shares18
  2. Aug 31, 20268-K Bylaws or fiscal year changed; Shareholder vote19
  3. Jul 2, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change20
  4. Dec 31, 20258-K Shareholder vote21
  5. Dec 19, 20258-K Shareholder vote22
  6. Nov 12, 20258-K Executive or director change23
  7. Oct 31, 20258-K Entered a material agreement; Unregistered sale of shares24
  8. May 6, 20258-K Shareholder vote25
  9. Apr 11, 20258-K Listing notice or transfer26
  10. Mar 14, 20258-K Executive or director change27
  11. Mar 7, 20258-K Entered a material agreement; Unregistered sale of shares28
  12. Dec 26, 20248-K Bylaws or fiscal year changed; Shareholder vote29
  13. May 20, 2016New chief executive Timothy Warbington becomes CEO12

Calendar

Coming up

  1. Nov 6, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.48) a share, on Nov 7, 2025.30

Drug trials and FDA: coming up

  1. Jan 20, 2027Phase 1/2 trial readout expected Phase 1/2 trial of CELZ-201-DDT in Chronic Low-back Pain: primary completion expected Jan 20, 2027 (ClinicalTrials.gov NCT06053242).31
  2. Jan 31, 2027Phase 1/2 trial readout expected Phase 1/2 trial of CELZ-201 Administration in Type 1 Diabetes: primary completion expected Jan 31, 2027 (ClinicalTrials.gov NCT05626712).32

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

140 filings to the SEC since October 2021: 12 annual reports, 15 quarterly reports, 26 major events, 15 insider forms, 11 large holders, 1 private raises, 60 other. The latest 20:

  1. Oct 1, 2026SCHEDULE 13D EDGAR
  2. Sep 25, 20264 EDGAR
  3. Sep 25, 20268-K EDGAR
  4. Aug 31, 20268-K EDGAR
  5. Aug 7, 202610-Q EDGAR
  6. Aug 3, 2026424B3 EDGAR
  7. Jul 31, 2026EFFECT EDGAR
  8. Jul 24, 2026S-3 EDGAR
  9. Jul 14, 2026DEF 14A EDGAR
  10. Jul 2, 20268-K EDGAR
  11. Jul 1, 2026PRE 14A EDGAR
  12. Jun 30, 2026RW EDGAR
  13. Jun 26, 2026S-1/A EDGAR
  14. Jun 25, 2026S-1 EDGAR
  15. May 28, 2026DRS EDGAR
  16. May 8, 202610-Q EDGAR
  17. Apr 24, 202610-K/A EDGAR
  18. Mar 20, 202610-K EDGAR
  19. Dec 31, 20258-K EDGAR
  20. Dec 19, 20258-K EDGAR

The 140 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 11 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 19, 2025Finger Michael H.DirectorSale750$5.75$4.3KForm 4
Feb 18, 2025Finger Michael H.DirectorSale750$5.00$3.8KForm 4
Jun 28, 2023Warbington TimothyPresident & CEOBuy200$4.36$872Form 4
Jun 27, 2023Warbington TimothyPresident & CEOBuy800$4.44$3.6KForm 4
Nov 22, 2022Warbington TimothyPresident & CEOBuy10,000$0.39$3.9KForm 4
Nov 21, 2022Warbington TimothyPresident & CEOBuy15,000$0.40$6.0KForm 4
Sep 27, 2022Finger Michael H.DirectorBuy2,000$0.50$1.0KForm 4
Sep 27, 2022Warbington TimothyPresident & CEOBuy20,000$0.50$10.0KForm 4
Sep 22, 2022Warbington TimothyPresident & CEOBuy12,000$0.54$6.5KForm 4
Sep 21, 2022Warbington TimothyPresident & CEOBuy30,000$0.61$18.4KForm 4
Jun 14, 2022Finger Michael H.DirectorBuy10,000$0.70$7.0KForm 4
Jun 6, 2022Warbington TimothyPresident & CEOBuy25,000$0.91$22.9KForm 4
May 20, 2022Finger Michael H.DirectorBuy6,500$1.50$9.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$17.0M 2022–2022
Money received by yearMoney received by year, 2022–2022: $17.0M in all. Private raises (Form D) $17.0M.$0$5M$10M$15M$20M2022 · Private raises (Form D): $17.0M2022
Figures by year
YearPrivate raises (Form D)Total
2022$17.0M$17.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. May 3, 2022Raised $17 million in a private offering of equity17 Form D: 18 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Hudson Bay Capital Management LP135,170$196.0K0.0%New
Anson Funds Management LP105,549$153.0K0.0%New
Armistice Capital, LLC42,000$60.9K0.0%New
XTX Topco Ltd26,559$38.5K0.0%+12,299
Geode Capital Management, LLC25,799$37.4K0.0%−12,491
Vanguard Capital Management LLC20,350$29.5K0.0%No change
Vanguard Fiduciary Trust Co5,518$8.0K0.0%No change
Tower Research Capital LLC (TRC)4,853$7.0K0.0%+2,761
Global Retirement Partners, LLC4,118$6.0K0.0%New
UBS Group AG2,061$3.0K0.0%+2,060
Morgan Stanley514$7450.0%−20
Barclays PLC54$780.0%New
SBI Securities Co., Ltd.43$620.0%+42

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.1
  • CIK0001187953
  • Employer ID (EIN)87-06222843
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address211 E. Osborn Rd., Phoenix, AZ 850121
  • Phone480-399-28221
  • Shares outstanding6,592,557 as of Aug 7, 202611
  • Public float$4.6M as of Jun 30, 20253
  • AuditorHaynie, Salt Lake City, Utah PCAOB ID 457; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceSep 13, 20021
  • Filings409 in all: 8-K (105), 10-Q (53), 4 (52), 10-K (18), D (17), CORRESP (15), UPLOAD (14), 3 (10)1
    All 49 form types

    10-K/A (9), EFFECT (9), DEF 14A (8), 3/A (6), 424B3 (6), S-1 (6), SC 13G (6), 10-Q/A (5), DEF 14C (5), PRE 14A (5), PRE 14C (5), S-3 (5), SC 13G/A (5), RW (4), S-1/A (4), SC 13D/A (4), NT 10-Q (3), 144 (2), 4/A (2), 8-K/A (2), DRS (2), DRS/A (2), NT 10-K (2), 10-12G (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), CT ORDER (1), DEFR14C (1), DRSLTR (1), POS AM (1), PRER14A (1), PRER14C (1), REGDEX (1), SB-2 (1), SC 13D (1), SC 14F1 (1), SCHEDULE 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Jul 14, 2026
    Latest 8-K (8-K) Sep 25, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareCELZNASDAQ

From the cover page of the 10-K filed Mar 20, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. names in Item 1A of its 10-K filed Mar 20, 2026: 32 risks under these headings, as written.3

  • Risks Related to our Financial Position and Capital Needs
  • We have incurred recent losses and our future profitability is uncertain.
  • Even with the proceeds from our securities offerings, we will need additional capital to fund our operations as planned.
  • We have generated minimal revenues from our products and do not expect to generate revenues for the foreseeable future. We will not achieve profitability unless we generate increased revenues from our current or proposed products or therapies.
  • We expect to continue to incur significant financial losses in the future as we proceed with our Type I Diabetes (CELZ-201 CREATE-1) clinical trial, our AlloStemSpine® Chronic Lower Back Pain (CELZ-201 ADAPT) clinical trial, and our other planned clinical trials.
  • Risks Related to Product Development, Regulatory Approval and Commercialization
  • Our product candidates’ commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals, and the risks generally inherent in the development of biopharmaceutical products. If we are unable to successfully advance or develop our product candidates, our business will be materially harmed.
  • We may not be successful in our commercialization efforts for our proposed products and therapies, which may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
  • The results of our clinical trials may not support our product claims or may result in the discovery of adverse side effects.
  • We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals.
  • Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
  • Our autologous products are currently not eligible for reimbursement from public or private insurers.
The other 22 risks
  • The pharmaceutical business is subject to increasing government regulation and reform, including with respect to price controls, reimbursement, and access to therapies, which could adversely affect our future revenues and profitability.
  • United States federal and state privacy laws, and equivalent laws of other nations, may increase our costs of operation and expose us to civil and criminal sanctions.
  • Later discovery of previously unknown problems could limit our ability to market or sell our products or therapies and can expose us to product liability claims.
  • If we do not obtain required approvals in other countries in which we aim to market our products, we will be limited in our ability to export or sell the products in those markets.
  • We rely in part on third parties for research and clinical trials for our products and therapies.
  • We currently have a very limited marketing and sales organization and may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products and therapies, we may not be able to generate sufficient revenues to support our operations.
  • We rely upon third parties for the manufacture of our CaverStem® and FemCelz® disposable kits and are dependent on their quality and effectiveness.
  • We may be unable to compete effectively with marketed therapies or drugs targeting similar indications to our products and therapies.
  • Our business and operations would suffer in the event of computer system failures or security breaches.
  • We are subject to risks arising from the global outbreak of the COVID-19 coronavirus.
  • We are subject to risks arising from the wars in Ukraine and the Gaza Strip.
  • Risks Related to Our Intellectual Property
  • We may not be able to protect our proprietary rights.
  • We are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages or prohibit us from selling our product candidates.
  • We may need to initiate lawsuits to protect or enforce our intellectual property rights, which could be expensive and, if we lose, could cause us to lose some of our intellectual property rights, which would harm our ability to compete in the market.
  • Risks Related to Employee Matters
  • We are dependent on our executive officers, and we may not be able to pursue our current business strategy effectively if we lose them.
  • Our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards.
  • If we fail to comply with the U.S. federal Anti-Kickback Statute and similar state and foreign country laws, we could be subject to criminal and civil penalties and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third country programs, which would have a material adverse effect on our business and results of operations.
  • Risks Related To Our Common Stock
  • The market price of our common stock is highly volatile, and you could lose all or part of your investment.
  • If our shares of common stock are delisted from The Nasdaq Capital Market and become subject to the penny stock rules, it will be more difficult to trade our shares.
  • Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our securities.
  • We will indemnify and hold harmless our officers and directors to the maximum extent permitted by Nevada law.
  • Because we do not expect to pay dividends for the foreseeable future, investors seeking cash dividends should not purchase shares of common stock.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38